Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue 2, 2000, Pages 151-158

  De Gasparo, Marc ^a   Hess, Patrick ^b   Nuesslein Hildesheim, Barbara ^a   Bruneval, Patrick ^c   Clozel, Jean Paul ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c HÔPITAL BROUSSAIS   (France)

Author keywords

Angiotensin; Angiotensin converting enzyme; Angiotensin receptor antagonist; Hypertension; L NAME; Nitric oxide; Nitric oxide synthase; Renoprotection

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; ENALAPRIL; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ANIMAL; ARTICLE; BLOOD; BLOOD PRESSURE; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; HYPERTENSION; MALE; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL; VASCULAR ENDOTHELIUM;

ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENALAPRIL; ENDOTHELIUM, VASCULAR; HYPERTENSION; MALE; RATS; RATS, INBRED SHR; SURVIVAL ANALYSIS; TETRAZOLES; VALINE;

EID: 0034211628     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.019     Document Type: Article

References (38)

1. Komatsu K, Frohlich ED, Ono H, Ono Y, Numabe A, Willis GW. Glomerular dynamics and morphology of aged spontaneously hypertensive rats: effects of angiotensin converting enzyme inhibitors. Hypertension 1995;25:207-213.
2. Ono H, Ono Y, Frohlich ED. Nitric oxide synthase inhibition in spontaneously hypertensive rats. Systemic, renal, and glomerular hemodynamics. Hypertension 1995;26:249-255.
3. Sventek P. Li JS, Grove K, Deschepper CF, Schiffrin EL. Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats. Hypertension 1996;27:49-55.
4. Fujita H, Takeda K, Nakamura K et al. Role of nitric oxide in impaired coronary circulation and improvement by angiotensin II receptor antagonist in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1995;1:S148-150.
5. Usui M, Ichiki T, Katoh M, Egashira K, Takeshita A. Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension 1998;32:527-533.
6. Ono Y, Ono H, Frohlich ED. Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 1996;14:823-828.
7. Francischetti A, Ono H, Frohlich ED. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998;31:795-801.
8. Nakamura Y, Ono H, Frohlich ED. Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats. Hypertension 1999;34:273-278.
9. Blythe WB and Maddux FW. Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States from 1980 to 1986. Am J Kidney Dis 1991;18:33-37.
10. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2 - short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
11. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-616.
12. Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming system in humans. Am J Hypertens 1996;9:277-284.
13. Wolmy A, Clozel JP, Rein J, Mory P, Vogt P, Jurino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997;80:219-227.
14. Sweet CS, Emmert SC, Stabilito II, Ribeiro LGT. Increased survival in rats with congestive heart failure treated with enalapril. J Cardiovasc Pharmacol 1987;10:636-642.
15. Gervais M, Richer C, Fornes P, de Gasparo M, Giudicelli JF. Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. Fundam Clin Pharmacol 1999;13:635-645.
16. Frohlich ED. Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Arthus C. Corcoran Memorial Lecture. Hypertension 1997;29:188-193.
17. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998;31:349-355.
18. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997;100:264-269.
19. Siragy HM, de Gasparo M, Carey RM. Increased production of bradykinin and nitric oxide after angiotensin AT1 receptor blockade with valsartan. Hypertension 2000; in press.
20. Wada T, Kanagawa R, Ishimura Y, Inada Y, Nishikawa K. Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 1995; 13: 113-22.
21. Inada Y, Wada T, Ojima M et al. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1997; 19: 1070-99.
22. Kometani M, Hayashi N, Yamamoto S, Nakao K, Inukai T. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment. Arzneimittel-Forsch 1997;47:613-619.
23. Webb RL, Barclay BW, Navarrete AE, Wosu NJ, Sahota P. Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1998;20:775-793.
24. de las Heras N, Aragoncillo P, Maeso R et al. AT1 receptor antagonism reduces endothelial dysfunction and intimai thickening in atherosclerotic rabbits. Hypertension 1999;34:969-975.
25. Villa E, Rabano A, Cazes M, Cloarec A, Ruilope LM, Garcia-Robles R. Effects of UP269-6, a new angiotensin II receptor antagonist, and captopril on the progression of rat diabetic nephropathy. Am J Hypertens 1997;10:275-281.
26. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow JL, Keidar S. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 1999;44:579-587.
27. Kobayashi N, Higashi T, Hara K, Shirataki H, Matsuoka H. Effects of imidapril on NOS expression and myocardial remodelling in failing heart of Dahl salt-sensitive hypertensive rats. Cardiovasc Res 1999;44:518-526.
28. Montgomery HE, Kiernan LA, Whitworth CE et al. Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. J Hypertens 1998;16:635-643.
29. Mervaala EMA, Müller DN, Park JK et al. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999; 33:389-395.
30. Hilgers KF, Hartner A, Veelken R, Mann JFE. Angiotensin II type 1 receptor mediates macrophage infiltration into kidney cortex independent from blood pressure in hypertensive nephrosclerosis. Am Soc Nephrology, abstract 1751, November 7, 1999.
31. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
32. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
33. Cohn JN. Arteries, myocardium, blood pressure and cardiovascular risk: towards a revised definition of hypertension. J Hypertens 1998;16:2117-2124.
34. Luft FC, Mervaala E, Müller DN et al. Hypertension-induced end-organ damage. A new transgenic approach to an old problem. Hypertension 1999; 33:212-218.
35. Bakris GL, Siomos M, Kasprowicz S, Bolton WK, Hebert L, Catanzaro D, Janssen I Differential effects of valsartan (V) and lisinopril (L) on potassium (K+) homeostasis in hypertensive patients with nephropathy. Am J Hypertens 1999; 12:36A.
36. Black H, Graff A, Glazer R, Pincus J. Valsartan in combination with hydrochlorothiazide reduces the incidence of diuretic-induced hypokalemia: an integrated analysis of clinical data. J Human Hypertens 1999;13 (Suppl. 3) S17 (Abs P.63).
37. Burnier M and Brunner HR. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects. Exp Nepbrol 1996;4 Suppl 1:41-46.
38. Textor SC, Bravo EL, Fouad FM, Tarazi-RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982;73:719-725.